



危重症中体循环与 微循环的关系

安徽医科大学第一附属医院

张泓





何谓危重症？

- 衰竭的重要器官、系统急需支持
- 否则...死亡接踵而来
- 濒死状态



Critically ill patient

- definition —

Decompensation of the status of the patient leading without therapeutic intervention to the **multiorgan failure** and to **death**



何谓循环？

- **circulatory system is ... heart, veins, capillaries, arteries, lymph vessels, lymph glands, ...**
- **...to supply the body tissues with nourishment and collect waste materials**

体循环&微循环：大河——小溪？



- Systemic

HIGH RES


HIGH PRE
(120/80 mmHg)

- Pulmonary

LOW RES

LOW PRE
(25/10 mmHg)

heart





循环系统的功能

- **Heart:** pumps blood
- **Arterial System:** oxygenated blood to tissues
- **Venous system:** deoxygenated blood back to heart
- **Capillaries:** exchange gases, nutrients, and wastes



循环系统的功能

- **Distribute** nutrients through tissues of the body
- **Transport and exchange** oxygen and carbon dioxide
- **Remove** waste materials
- **Distribute** secretions of endocrine glands
- **Prevent** excessive bleeding
- **Prevent** infection
- **Regulate** body temperature



何谓微循环？


- 微循环（microcirculation）这个名词是1954年在美国召开的第一届国际微循环会议上正式提出的。指微（细）动脉和微（细）静脉之间微血管的血液循环。
- The microcirculation is the 血流 through 血管 smaller than 100 μm

Keywords:

管径
 $\leq 100\mu\text{m}$



微循环的构成



(a) Sphincters open

Copyright © 2008 Pearson Education, Inc., publishing as Benjamin Cummings.

小动脉

(50~100 μm)

毛细血管

(5~10 μm)

小静脉

(~20 μm)

后小动脉

(10~20 μm)

毛细血管前括约肌





体循环和微循环


- **Pressure inside is 20~40 mmHg**
- **5% of the blood is in capillaries**
- **exchange of gases, nutrients, and wastes**
- **flow is slow and continuous**

Capillaries are close! Every cell in the body is no more than two cell diameters from a capillary.

真正将血流从心血管系统运送到组织细胞的是微循环




肺循环和微循环






肺循环和微循环

- gas exchange: across small pulmonary arterial vessels [histologically not capillaries-functionally capillaries] & pulmonary capillaries
- there are about 280 billion pulmonary capillaries for about 300 million alveoli resulting in a gas exchange surface of about 60-100 m²





外界环境中的物质





Circulation

Circulatory abnormalities

Intravascular
volume
depletion

Peripheral
vasodilatation

Myocardial
depression

Increased
metabolism

Imbalance between systemic O₂ delivery and O₂ demand

Global tissue hypoxia

Shock

Multiple organ failure

Death







O₂输送的调节

Normal

Abnormal

$$BP = CO \times SVR$$




$$QO_2 = Flow \times O_2 \text{ content}$$





Mechanism of regional tissue dysoxia (细胞病性缺氧)



Global hypoperfusion

Microcirculatory shunting

Mitochondrial failure

Crit Care Med 1995; 23: 1217

Lancet 2002; 360: 219





Seven Stages of Cell Death


- 1. **Normal** cell
Normal sodium –potassium pump
- 2. **Hypoxia**: intracellular ischemia occurs; anaerobic metabolism begins; lactic acid builds up in cell; leading to metabolic acidosis; causes the sodium potassium pump to fail.
- 3. **Ion shift** occurs Sodium rushes into the cell bringing water with it.



Seven Stages of Cell Death

- 4. **Cell swelling** occurs.
- 5. **Mitochondrial swelling** occurs; production of ATP ceases.
- 6. **Intracellular disruption** releases lysosomes, cell membrane begins to break.
- 7. **Cell destruction** begins leading to **tissue death**.

Microcirculatory Mitochondrial Distress Syndrome







Specific organ failure

- **Circulation**
- **Lung**
- **GI tract**
- **Liver**
- **Kidney**
- **Nervous system**



肺 (Lung)





造血系统 (Hepatosplanic system)





Figure 16. Diagram of the epithelium of an intestinal villus and crypt.

- Feedback loop
- Sepsis depress the gut's normal barrier



(肾脏) Kidney



- **Acute tubular necrosis**
- **Systemic hypotension**
- **direct renal vasoconstriction,**
- **cytokines :TNF**
- **Endotoxin ,FMLP, a three amino acid (fMet-Leu-Phe) chemotactic peptide...**



神经系统 (Nervous system)

- **Encephalopathy:**
agitation, confusion, coma
- **NO in the brain induce apoptosis in neurons**
- **Hypothalamic-pituitary-adrenal axis**
Sympathetic nervous system
Cholinergic anti-inflammatory pathway




代谢变化 (Metabolic alternations)

- Intensive insulin therapy with tight glycemic control resulted in survival benefit
- GLUT-1,2,3 :insulin-independent
hepatocyte, neurons, gut mucosal,renal tubular,immune and endothelial cell
- GLUT-4:insulin-dependent
heart, skeletal muscle, adipose tissue



体循环-微循环-细胞病性缺氧





循环障碍的急诊管理策略

- 评估（院前、急诊抢救室、ICU）
- 动态监测
- 综合治疗措施



血流动力学监测

- **Microcirculation**
- **Esophageal Doppler**
- **NICO** (partial CO₂ rebreathing method)
- **PiCCO**
- **RVEF PAC – RVEDV/RVEDVI**
- **ScvO₂ CVP**
- **HR**
- **BP**
- **T**
- **RR**
- **Urine output**
- **Response**
- **Lactate**




微循环监测

- **Nailfold videomicroscopy**
- **Laser doppler (skin, muscle, gut)**
- **GI tonometry (pCO₂)**
- **Near-infrared spectroscopy**
- **Oxygen electrodes (pO₂)**
- **Orthogonal polarization spectral imaging (sublingual mucosa)**




Orthogonal polarization spectral (OPS)

Cardiogenic Shock




Normal Tongue



Cardiogenic Shock

Curr Opin Crit Care. 2001 Jun;7(3):200-3
Curr Opin Crit Care. 2005 Jun;11(3):240-4


Goal-Directed Therapy



大河满了——小溪？



Goal-directed Therapy



Goal-directed Therapy



**“Upstream” endpoints
of resuscitation**

Hemodynamic parameters

- Preload (CVP, PCWP)
- Afterload (MAP, SVR)
- Contractility (SV)
- Heart rate (BPM)
- Shock index (HR/SBP)
- Coronary perfusion pressure

DO₂ parameters

- PaO₂
- Hemoglobin
- Cardiac output



Goal-directed Therapy



**“Upstream” endpoints
of resuscitation**


Hemodynamic parameters

- Preload (CVP, PCWP)
- Afterload (MAP, SVR)
- Contractility (SV)
- Heart rate (BPM)
- Shock index (HR/SBP)
- Coronary perfusion pressure

DO₂ parameters

- PaO₂
- Hemoglobin
- Cardiac output

Microcirculation



Goal-directed Therapy



“Upstream” endpoints of resuscitation


Hemodynamic parameters

- Preload (CVP, PCWP)
- Afterload (MAP, SVR)
- Contractility (SV)
- Heart rate (BPM)
- Shock index (HR/SBP)
- Coronary perfusion pressure


DO₂ parameters

- PaO₂
- Hemoglobin
- Cardiac output

Microcirculation




“Downstream” markers of the effectiveness of resuscitation





关注“下游”标志物

- **SvO₂**
- **Lactate**
- **(a-v)CO₂**
- **Base deficit**
- **pHi**
- **PsiCO₂**
- **mediators**





血管活性药物

- 提供充足的组织氧供
- 维持重要器官功能
- 维持全身血压

The main factors influencing blood pressure are:

- **Cardiac output (CO)** ▶ 驱因，正性肌力药物
- **Peripheral resistance (PR)** ▶ 血管活性药物
- **Blood volume** ▶ 晶、胶体，血制品
- 联合用药减少不良反应



Catecholamines and Sites of Action

Drug	Site of Action	Dose Range ($\mu\text{g}/\text{kg}/\text{min}$)	Hemodynamic Effects	Adverse Effects
Isoproterenol	β_1 - and β_2 -receptors No α_1 effects	0.05-0.5 (β only)	\uparrow inotropy, \uparrow HR, \downarrow MAP via β_1 - and β_2 -receptors Reduced PVR and SVR	Tachycardia and arrhythmias
Dopamine	β_1 - and β_2 -receptors α_1 -receptors in periphery	0.5-5 (dopaminergic); 5-10 (β and dopaminergic); >10 (α and β); >20 (α)	\uparrow inotropy, \uparrow MAP, \uparrow PVR. At <10 $\mu\text{g}/\text{kg}$, inotropic effects predominate Renal effects at <3 $\mu\text{g}/\text{kg}$	Tachycardia post-CPB Increasing α effects >10 $\mu\text{g}/\text{kg}/\text{min}$ leads to increases in SVR and PVR.
Dobutamine	DA ₁ and DA ₂ receptors in the kidney β_1 - and β_2 -receptors ($\beta_1 > \beta_2$)	5-10 (α and β)	\uparrow inotropy, \uparrow HR via β_1 - and β_2 -receptors	Tissue necrosis Tachycardia post-CPB. Vasodilator effects may
Epinephrine	β_1 -, β_2 -, and α_1 -receptors	0.01-0.02 (β); 0.02-0.5 (α and β)	Dilates coronary arteries \uparrow inotropy, \uparrow HR and MAP via β_1 -receptors. Vasodilator at low doses via β_2 -receptors	Tachycardia Vasoconstriction at higher doses via α -receptors Hyperglycemia Myocardial necrosis
Minimal β_2 effects				increased afterload
CPB, cardiopulmonary bypass; HR, heart rate; MAP, mean arterial pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.				

Catecholamines and Sites of Action

Drug	Site of Action	Dose Range ($\mu\text{g}/\text{kg}/\text{min}$)	Hemodynamic Effects	Adverse Effects
Isoproterenol	β_1 - and β_2 -receptors No α_1 effects	0.05-0.5 (β only)	\uparrow inotropy, \uparrow HR, \downarrow MAP via β_1 - and β_2 -receptors Reduced PVR and SVR	Tachycardia and arrhythmias
Dopamine	β_1 - and β_2 -receptors α_1 -receptors in periphery DA ₁ and DA ₂ receptors in the kidney	0.5-5 (dopaminergic); 5-10 (β and dopaminergic); >10 (α and β); >20 (α)	\uparrow inotropy, \uparrow MAP, \uparrow PVR. At <10 $\mu\text{g}/\text{kg}$, inotropic effects predominate Renal effects at <3 $\mu\text{g}/\text{kg}$	Tachycardia post-CPB Increasing α effects >10 $\mu\text{g}/\text{kg}/\text{min}$ leads to increases in SVR and PVR. Tissue necrosis
Dobutamine	β_1 - and β_2 -receptors ($\beta_1 > \beta_2$) Minimal α_1 effects	5-10 (α and β)	\uparrow inotropy, \uparrow HR via β_1 - and β_2 -receptors \downarrow PVR and SVR Dilates coronary arteries	Tachycardia post-CPB. Vasodilator effects may result in reduced MAP
Epinephrine	β_1 -, β_2 -, and α_1 -receptors	0.01-0.02 (β); 0.02-0.5 (α and β)	\uparrow inotropy, \uparrow HR and MAP via β_1 -receptors. Vasodilator at low doses via β_2 -receptors	Tachycardia Vasoconstriction at higher doses via α -receptors Hyperglycemia Myocardial necrosis
Norepinephrine	α_1 - and β_1 -receptors Minimal β_2 effects	0.01-0.5 (α and β)	\uparrow MAP via α_1 -receptors	Vasoconstriction and increased afterload

CPB, cardiopulmonary bypass; HR, heart rate; MAP, mean arterial pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance

Catecholamines and Sites of Action				
Drug	Site of Action	Dose Range ($\mu\text{g}/\text{kg}/\text{min}$)	Hemodynamic Effects	Adverse Effects
	No α_1 effects		MAP via β_1 - and β_2 -receptors	arrhythmias
Dopamine	β_1 - and β_2 -receptors	0.5-5	Reduced PVR and SVR \uparrow inotropy, \uparrow MAP,	Tachycardia post-CPB
		5-10 (β and dopaminergic); >10 (α and β); >20 (α)	At <10 $\mu\text{g}/\text{kg}$, inotropic effects predominate Renal effects at <3 $\mu\text{g}/\text{kg}$	>10 $\mu\text{g}/\text{kg}/\text{min}$ leads to increases in SVR and PVR. Tissue necrosis
Dobutamine	DA ₁ and DA ₂ receptors in the kidney β_1 - and β_2 -receptors ($\beta_1 > \beta_2$) Minimal α_1 effects	5-10 (α and β)	\uparrow inotropy, \uparrow HR via β_1 - and β_2 -receptors \downarrow PVR and SVR	Tachycardia post-CPB. Vasodilator effects may result in reduced MAP
Epinephrine	β_1 -, β_2 -, and α_1 -receptors	0.01-0.02 (β); 0.02-0.5 (α and β)	Dilates coronary arteries \uparrow inotropy, \uparrow HR and MAP via β_1 -receptors. Vasodilator at low doses via β_2 -receptors	Tachycardia Vasoconstriction at higher doses via α -receptors Hyperglycemia Myocardial necrosis
Norepinephrine	α_1 - and β_1 -receptors Minimal β_2 effects	0.01-0.5 (α and β)	\uparrow MAP via α_1 -receptors	Vasoconstriction and increased afterload

CPB, cardiopulmonary bypass; HR, heart rate; MAP, mean arterial pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.

Bohn (2006). Inotropic Agents in Heart Failure. Heart Failure in Children and Young Adults. Chang & Towbin.



Catecholamines and Sites of Action

Drug	Site of Action	Dose Range ($\mu\text{g}/\text{kg}/\text{min}$)	Hemodynamic Effects	Adverse Effects
Isoproterenol	β_1 - and β_2 -receptors No α_1 effects	0.05-0.5 (β only)	\uparrow inotropy, \uparrow HR, \downarrow MAP via β_1 - and β_2 -receptors Reduced PVR and SVR	Tachycardia and arrhythmias
Dobutamine	α_1 -receptors in periphery DA ₁ and DA ₂ receptors in the kidney β_1 - and β_2 -receptors	(dopaminergic); 5-10 (β and dopaminergic); >10 (α and β); >20 (α) 5-10 (α and β)	\uparrow PVR. At <10 $\mu\text{g}/\text{kg}$, inotropic effects predominate Renal effects at <3 $\mu\text{g}/\text{kg}$ \uparrow inotropy, \uparrow HR via	Increasing α effects >10 $\mu\text{g}/\text{kg}/\text{min}$ leads to increases in SVR and PVR. Tissue necrosis Tachycardia post-CPB.
Epinephrine	Minimal α_1 effects β_1 -, β_2 -, and α_1 -receptors	0.01-0.02 (β); 0.02-0.5 (α and β)	\downarrow PVR and SVR Dilates coronary arteries \uparrow inotropy, \uparrow HR and MAP via β_1 -receptors. Vasodilator at low doses via β_2 -receptors	result in reduced MAP Tachycardia Vasoconstriction at higher doses via α -receptors Hyperglycemia Myocardial necrosis
Norepinephrine	α_1 - and β_1 -receptors Minimal β_2 effects	0.01-0.5 (α and β)	\uparrow MAP via α_1 -receptors	Vasoconstriction and increased afterload

CPB, cardiopulmonary bypass; HR, heart rate; MAP, mean arterial pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.

Bohn (2006). Inotropic Agents in Heart Failure. Heart Failure in Children and Young Adults. Chang & Towbin.



Catecholamines and Sites of Action

Drug	Site of Action	Dose Range (µg/kg/min)	Hemodynamic Effects	Adverse Effects
Isoproterenol	β ₁ - and β ₂ -receptors No α ₁ effects	0.05-0.5 (β only)	↑ inotropy, ↑ HR, ↓ MAP via β ₁ - and β ₂ -receptors Reduced PVR and SVR	Tachycardia and arrhythmias
Dopamine	β ₁ - and β ₂ -receptors α ₁ -receptors in periphery DA ₁ and DA ₂ receptors in the kidney	0.5-5 (dopaminergic); 5-10 (β and dopaminergic); >10 (α and β); >20 (α)	↑ inotropy, ↑ MAP, ↑ PVR. At <10 µg/kg, inotropic effects predominate Renal effects at <3 µg/kg	Tachycardia post-CPB Increasing α effects >10 µg/kg/min leads to increases in SVR and PVR. Tissue necrosis
Dobutamine	(β ₁ > β ₂) Minimal α ₁ effects	5-10 (α and β)	β ₁ - and β ₂ -receptors ↓ PVR and SVR Dilates coronary arteries ↑ inotropy, ↑ HR and	Vasodilator effects may result in reduced MAP Tachycardia
Epinephrine	β ₁ -, β ₂ -, and	0.01-0.02 (β);	Vasodilator at low doses via β ₂ -receptors	doses via α-receptors Hyperglycemia Myocardial necrosis Vasoconstriction and increased afterload
Norepinephrine	α ₁ - and β ₁ -receptors Minimal β ₂ effects	0.01-0.5 (α and β)	↑ MAP via α ₁ -receptors	

CPB, cardiopulmonary bypass; HR, heart rate; MAP, mean arterial pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.



肾上腺素&微循环

- 肾上腺素：减少微循环血流，导致缺血；可能是导致心肺复苏后神经功能恢复差的原因之一！

Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: a prospective study

Arnaldo Dubin^{1,2}, Mario O Pozo³, Christian A Casabella¹, Fernando Pálizas Jr³, Gastón Murias³, Miriam C Moseinco¹, Vanina S Kanoore Edul^{1,2}, Fernando Pálizas³, Elisa Estenssoro¹ and Can Ince⁵

Abstract

Introduction Our goal was to assess the effects of titration of a norepinephrine infusion to increasing levels of mean arterial pressure (MAP) on sublingual microcirculation.

Methods Twenty septic shock patients were prospectively studied in two teaching intensive care units. The patients were mechanically ventilated and required norepinephrine to maintain a mean arterial pressure (MAP) of 65 mmHg. We measured systemic hemodynamics, oxygen transport and consumption (DO_2 and VO_2), lactate, albumin-corrected anion gap, and gastric intramucosal-arterial PCO_2 difference (ΔPCO_2). Sublingual microcirculation was evaluated by sidestream darkfield (SDF) imaging. After basal measurements at a MAP of 65 mmHg, norepinephrine was titrated to reach a MAP of 75 mmHg, and then to 85 mmHg. Data were analyzed using repeated measurements ANOVA and Dunnett test. Linear trends between the different variables and increasing levels of MAP were calculated.

Results Increasing doses of norepinephrine reached the target values of MAP. The cardiac index, pulmonary pressures,

systemic vascular resistance, and left and right ventricular stroke work indexes increased as norepinephrine infusion was augmented. Heart rate, DO_2 and VO_2 , lactate, albumin-corrected anion gap, and ΔPCO_2 remained unchanged. There were no changes in sublingual capillary microvascular flow index (2.1 ± 0.7 , 2.2 ± 0.7 , 2.0 ± 0.8) and the percent of perfused capillaries (72 ± 26 , 71 ± 27 , $67 \pm 32\%$) for MAP values of 65, 75, and 85 mmHg, respectively. There was, however, a trend to decreased capillary perfused density (18 ± 10 , 17 ± 10 , 14 ± 2 vessels/mm², respectively, ANOVA $P = 0.09$, linear trend $P = 0.045$). In addition, the changes of perfused capillary density at increasing MAP were inversely correlated with the basal perfused capillary density ($R^2 = 0.95$, $P < 0.0001$).

Conclusions Patients with septic shock showed severe sublingual microcirculatory alterations that failed to improve with the increases in MAP with norepinephrine. Nevertheless, there was a considerable interindividual variation. Our results suggest that the increase in MAP above 65 mmHg is not an adequate approach to improve microcirculatory perfusion and might be harmful in some patients.



去甲肾上腺素&微循环

- 去甲肾上腺素：**MAP**升高，但乳酸仍高，
毛细血管密度降低！

Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: a prospective study

Arnaldo Dubin^{1,2}, Mario O Pozo³, Christian A Casabella¹, Fernando Pálizas Jr³, Gastón Murias³, Miriam C Moseinco¹, Vanina S Kanoore Edul^{1,2}, Fernando Pálizas³, Elisa Estenssoro¹ and Can Ince⁵

Abstract

Introduction Our goal was to assess the effects of titration of a norepinephrine infusion to increasing levels of mean arterial pressure (MAP) on sublingual microcirculation.

Methods Twenty septic shock patients were prospectively studied in two teaching intensive care units. The patients were mechanically ventilated and required norepinephrine to maintain a mean arterial pressure (MAP) of 65 mmHg. We measured systemic hemodynamics, oxygen transport and consumption (DO_2 and VO_2), lactate, albumin-corrected anion gap, and gastric intramucosal-arterial PCO_2 difference (ΔPCO_2). Sublingual microcirculation was evaluated by sidestream darkfield (SDF) imaging. After basal measurements at a MAP of 65 mmHg, norepinephrine was titrated to reach a MAP of 75 mmHg, and then to 85 mmHg. Data were analyzed using repeated measurements ANOVA and Dunnett test. Linear trends between the different variables and increasing levels of MAP were calculated.

Results Increasing doses of norepinephrine reached the target values of MAP. The cardiac index, pulmonary pressures,

systemic vascular resistance, and left and right ventricular stroke work indexes increased as norepinephrine infusion was augmented. Heart rate, DO_2 and VO_2 , lactate, albumin-corrected anion gap, and ΔPCO_2 remained unchanged. There were no changes in sublingual capillary microvascular flow index (2.1 ± 0.7 , 2.2 ± 0.7 , 2.0 ± 0.8) and the percent of perfused capillaries (72 ± 26 , 71 ± 27 , $67 \pm 32\%$) for MAP values of 65, 75, and 85 mmHg, respectively. There was, however, a trend to decreased capillary perfused density (18 ± 10 , 17 ± 10 , 14 ± 2 vessels/ mm^2 , respectively, ANOVA $P = 0.09$, linear trend $P = 0.045$). In addition, the changes of perfused capillary density at increasing MAP were inversely correlated with the basal perfused capillary density ($R^2 = 0.95$, $P < 0.0001$).

Conclusions Patients with septic shock showed severe sublingual microcirculatory alterations that failed to improve with the increases in MAP with norepinephrine. Nevertheless, there was a considerable interindividual variation. Our results suggest that the increase in MAP above 65 mmHg is not an adequate approach to improve microcirculatory perfusion and might be harmful in some patients.



Key Concepts

- The predominant β -AR in the heart is the β_1 -AR (75%).
- β_2 -ARs are largely found in vascular smooth muscle.
- α_1 -ARs predominate in vascular smooth muscle although they are present in the neonatal myocardium.



Key Concepts

- **Catacholamines are good in the short term for hemodynamic support but most increase myocardial oxygen demand, increase diastolic pressures, and can lead to apoptosis**
- **PDE inhibitors, while increasing intracellular Ca^+ , are lusiotropic and inotropic agents that do not increase myocardial O_2 demand and are not associated with tachyphylaxis.**



Key Concepts

- **A strategy of combining a PDE inhibitor with a catecholamine may be the best approach to support of the myocardium and circulation.**
- **Most inotropic agents to date have a common final intracellular pathway of increased intracellular Ca^+ , which may ultimately lead to cell (myocyte) death.**



something better?

- **A new generation of inotropic agents known as calcium-sensitizing agents achieve their positive inotropic effects without an increase in intracellular Ca^{+} or myocardial O_2 consumption. Unfortunately their early studies of the first of these drugs demonstrated less benefit than was anticipated**

Levosimendan





复苏

- **Resuscitation**
 - Resuscitation goals
 - Time
 - CV parameters
 - Fluid management
 - Crystalloid vs. colloid
 - Vasopressor management
- **“Low-dose” corticosteroid therapy**
- **Microvascular circulation**



复苏目标

- **BP** **MAP>65 mmHg/SBP>90 mmHg**
- **CVP** **8-12 mmHg**
- **Urine output** **0.5-1 ml/kg/hr**
- **ScvO₂** **>70%**
- **Hgb** **>70-100 g/L**
- **pH** **>7.30**
- **Lactate** **<4**

**However time frame is likely
as important as absolute goals!!**





Conclusion


- **Prevention**
- **MET (medical emergent team)**
- **Early goal directed management**
- **Sepsis protocol**
- **Organ supportive and replacement treatment**

“Microcirculation Recruitment Manoeuvres”

Open the microcirculation and keep it open by support of the pump, fluids, vasodilators and restricted use of vasopressor agents.




Impact of medical emergency team on unexpected cardiac arrests




Bellomo R et al. *Crit Care Med* 2004;32:916-921.





Impact of Medical Emergency Team on ARF requiring Renal Replacement Therapy



Bellomo R et al. *Crit Care Med* 2004;32:916-921.





存在问题

- 究竟有无疗效确切的改善微循环的药物？
- 改善微循环，微循环能否充分复苏？
- 微循环充分复苏，患者预后能否切实得到改善？

路漫漫其修远兮，
吾将上下而求索！





*Thank you for
your attention!*

